An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of BV100 Administered as Single Intravenous In-fusion to Subjects With Renal Impairment
Latest Information Update: 20 Jan 2023
At a glance
- Drugs Rifabutin (Primary)
- Indications Nosocomial infections; Nosocomial pneumonia
- Focus Pharmacokinetics
- Sponsors BioVersys
- 16 Jan 2023 Status changed from active, no longer recruiting to completed.
- 06 Oct 2022 Status changed from completed to active, no longer recruiting.
- 28 Jun 2022 Planned End Date changed from 30 Apr 2022 to 30 Sep 2022.